retatrutide vs semaglutide vs tirzepatide 2026 Retatrutide for weight loss: Study

Compounded tirzepatide is billed under J3490 with the compounding pharmacy NDC number

Weight loss may improve testosterone levels, potentially enhancing libido, though the timeline and individual response vary considerably

October 2, 2024: The FDA updated the status for tirzepatide injections on the shortage list from Currently in Shortage to Resolved. This change meant that Tirzepatide injections, marketed under the brand names Zepbound and Mounjaro by Eli Lilly, could no longer be compounded by 503A Compounding Pharmacies or 503B Outsourcing Facilities

Compounded GLP-1s may not match a branded option exactly

For that reason, technical sourcing decisions often include purity review, storage validation, and protocol matching to the underlying model rather than broad generalisation